As we all know, EGFR-mutated non-small-cell lung cancer was highly sensitive to a variety of EGFR inhibitors [42,43,44], and our results also predict that EGFR was the responsive gene of Vandetanib, Lapatinib, Gefitinib, Canertinib, and Afatinib. This evidence concerns the gene EGFR and non-small cell lung carcinoma.